All In Biotech

Drug Trial Radar · NCT07241039

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Nov 20, 2025

Primary completion

Apr 2029

Study completion Oct 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors. ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide. In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent questionnaire, medical assessments, blood tests, and scans.

Conditions

  • Advanced Squamous Tumors

Interventions

  • ABBV-711Drug

    Oral Tablet

  • BudigalimabDrug

    Intravenous Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 5 Years
  2. Best overall Response (BOR)Time frame: Up to Approximately 5 Years

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • City Of Hope Comprehensive Cancer Center /ID# 276550

    Duarte, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432

    Irvine, California · Recruiting

  • University of Chicago Medical Center /ID# 276638

    Chicago, Illinois · Recruiting

  • START Midwest /ID# 272505

    Grand Rapids, Michigan · Recruiting

  • Carolina BioOncology Institute /ID# 272380

    Huntersville, North Carolina · Recruiting

  • Next Oncology Dallas /ID# 276659

    Irving, Texas · Recruiting

  • Princess Margaret Cancer Centre /ID# 276852

    Toronto, Ontario, Canada · Recruiting

  • CHUM - Centre hospitalier de l Universite de Montreal /ID# 277586

    Montreal, Quebec, Canada · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 276799

    Haifa, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 276800

    Jerusalem, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 276798

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • National Cancer Center Hospital East /ID# 276585

    Kashiwa-shi, Chiba, Japan · Recruiting

  • Kansai Medical University Hospital /ID# 276586

    Hirakata-shi, Osaka, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.